Dupixent is already approved to treat a range of inflammatory diseases including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, making $6 billion in global sales last ...

It is not known whether this is caused by DUPIXENT. Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, a feeling of pins and needles or numbness ...

Dupixent is FDA approved for adults and children ... is by how much the body surface area is affected and the severity of the rash or itch that can affect activities of daily living.

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Dupixent topped Rx and over-the-counter (OTC) pharma brands for ad impressions during Q1 2025, according to data released by iSpot.tv on Monday afternoon. The Regeneron and Sanofi brand for asthma and ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...